Canagliflozin (Renal) — Membership Pricing

Other medications in Diabetes & Metabolism

• Cinacalcet
• Dapagliflozin
• Dapagliflozin (CKD)
• Dulaglutide
• Empagliflozin
• Etelcalcetide
• Exenatide
• Finerenone

About Canagliflozin (Renal)

Canagliflozin renal is a vital medication for individuals managing type 2 diabetes and chronic kidney disease, working to protect kidney function and improve overall health. Understanding its benefits and how it works is crucial. At TheDrugClub, we believe access to essential medications shouldn't break the bank. Discover how our membership can provide significant savings on canagliflozin and many other prescriptions.

Canagliflozin, often referred to as "canagliflozin renal" in the context of its kidney-protective benefits, is a prescription medication primarily used to treat adults with type 2 diabetes. Beyond its role in blood sugar control, it's specifically indicated to reduce the risk of end-stage kidney disease, cardiovascular death, and hospitalization for heart failure in patients with type 2 diabetes and diabetic kidney disease. It represents a significant advancement in managing the complex interplay between diabetes and kidney health, offering hope for slowing the progression of chronic kidney disease (CKD).

How Canagliflozin Works to Protect Your Kidneys

Canagliflozin belongs to a class of drugs known as SGLT2 inhibitors (sodium-glucose co-transporter 2 inhibitors). These medications work in a unique way by targeting the kidneys. Normally, your kidneys reabsorb most of the glucose filtered from your blood. Canagliflozin, however, blocks the action of SGLT2 proteins in the kidneys, preventing the reabsorption of glucose and causing it to be excreted in the urine. This not only helps lower blood glucose levels but also contributes to several kidney-protective effects. By reducing pressure within the kidney's filtering units (glomeruli) and potentially decreasing inflammation, canagliflozin helps preserve kidney function over time, making it a cornerstone therapy for diabetic kidney disease.

Typical Costs and TheDrugClub Advantage

As a brand-name medication (marketed as Invokana), canagliflozin can be quite expensive. Without insurance, or with high-deductible

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Canagliflozin (Renal) is approved for (FDA label)

INVOKANA (canagliflozin) is indicated: as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus. to reduce the risk of major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction and nonfatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease (CVD). to reduce the risk of end-stage kidney disease (ESKD), doubling of serum creatinine, cardiovascular (CV) death, and hospitalization for heart failure in adults with type 2 diabetes mellitus and diabetic nephropathy with albuminuria greater than 300 mg/day.

Source: Read the full FDA label on DailyMed. Label effective date: June 11, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Canagliflozin (Renal) (FDA label)

INVOKANA 100 mg tablets are yellow, capsule-shaped, tablets with "CFZ" on one side and "100" on the other side. INVOKANA 300 mg tablets are white, capsule-shaped, tablets with "CFZ" on one side and "300" on the other side. Tablets: 100 mg, 300 mg ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: b9057d3b-b104-4f09-8a61-c61ef9d4a3f3. SPL document ID: cb98e349-535b-44ab-875f-f6d84382c49b. Label effective date: June 11, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Canagliflozin (Renal) (FDA label)

The following important adverse reactions are described below and elsewhere in the labeling: Diabetic Ketoacidosis in Patients with Type 1 Diabetes and Other Ketoacidosis [see Warnings and Precautions (5.1) ] Lower Limb Amputation [see Warnings and Precautions (5.2) ] Volume Depletion [see Warnings and Precautions (5.3) ] Genitourinary Infections, including Urosepsis, Pyelonephritis, Necrotizing Fasciitis of the Perineum (Fournier’s Gangrene), and Genital Mycotic Infections [see Warnings and Precautions (5.4) ] Hypoglycemia with Concomitant Use with Insulin or Insulin Secretagogues [see Warnings and Precautions (5.5) ] Hypersensitivity Reactions [see Warnings and Precautions (5.6) ] Bone Fracture [see Warnings and Precautions (5.7) ] Most common adverse reactions (5% or greater incidence): female genital mycotic infections, urinary tract infection, and increased urination ( 6.1 ).

Source: FDA prescribing information (DailyMed). Set ID: b9057d3b-b104-4f09-8a61-c61ef9d4a3f3. SPL document ID: cb98e349-535b-44ab-875f-f6d84382c49b. Label effective date: June 11, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Canagliflozin (Renal) (FDA label)

INVOKANA is contraindicated in patients with a serious hypersensitivity reaction to INVOKANA, such as anaphylaxis or angioedema [see Warnings and Precautions (5.6) and Adverse Reactions (6.1 , 6.2) ] . Serious hypersensitivity reaction to INVOKANA ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: b9057d3b-b104-4f09-8a61-c61ef9d4a3f3. SPL document ID: cb98e349-535b-44ab-875f-f6d84382c49b. Label effective date: June 11, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Canagliflozin (Renal) (FDA label)

Diabetic Ketoacidosis in Patients with Type 1 Diabetes Mellitus and Other Ketoacidosis : Consider ketone monitoring in patients at risk for ketoacidosis, as indicated. Assess for ketoacidosis regardless of presenting blood glucose levels and discontinue INVOKANA if ketoacidosis is suspected. Monitor patients for resolution of ketoacidosis before restarting ( 5.1 ). Lower Limb Amputation : Monitor patients for infections or ulcers of lower limb and institute appropriate treatment ( 5.2 ). Volume Depletion : May result in acute kidney injury. Before initiating INVOKANA, assess and correct volume status in patients with renal impairment, elderly patients, or patients on loop diuretics. Monitor for signs and symptoms during therapy ( 5.3 ). Genitourinary Infections, including Urosepsis, Pyelonephritis, Necrotizing Fasciitis of the Perineum (Fournier’s Gangrene), and Genital Mycotic Infections : Monitor patients for signs and symptoms of genitourinary infections and treat promptly, if indicated.

Source: FDA prescribing information (DailyMed). Set ID: b9057d3b-b104-4f09-8a61-c61ef9d4a3f3. SPL document ID: cb98e349-535b-44ab-875f-f6d84382c49b. Label effective date: June 11, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Canagliflozin (Renal) (FDA label)

Table 7: Clinically Significant Drug Interactions with INVOKANA UGT Enzyme Inducers Clinical Impact: UGT enzyme inducers decrease canagliflozin exposure which may reduce the effectiveness of INVOKANA. Intervention: For patients with eGFR 60 mL/min/1.73 m 2 or greater, if an inducer of UGTs is administered with INVOKANA, increase the dosage to 200 mg daily in patients currently tolerating INVOKANA 100 mg daily. The total daily dosage may be increased to 300 mg daily in patients currently tolerating INVOKANA 200 mg daily who require additional glycemic control. For patients with eGFR less than 60 mL/min/1.73 m 2 , if an inducer of UGTs is administered with INVOKANA, increase the dosage to 200 mg daily in patients currently tolerating INVOKANA 100 mg daily.

Source: FDA prescribing information (DailyMed). Set ID: b9057d3b-b104-4f09-8a61-c61ef9d4a3f3. SPL document ID: cb98e349-535b-44ab-875f-f6d84382c49b. Label effective date: June 11, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.